HRP20211574T1 - Inhibitori il-8 za primjenu u liječenju određenih uroloških poremećaja - Google Patents
Inhibitori il-8 za primjenu u liječenju određenih uroloških poremećaja Download PDFInfo
- Publication number
- HRP20211574T1 HRP20211574T1 HRP20211574TT HRP20211574T HRP20211574T1 HR P20211574 T1 HRP20211574 T1 HR P20211574T1 HR P20211574T T HRP20211574T T HR P20211574TT HR P20211574 T HRP20211574 T HR P20211574T HR P20211574 T1 HRP20211574 T1 HR P20211574T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- use according
- active compound
- pharmaceutical composition
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 11
- 208000014001 urinary system disease Diseases 0.000 title 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 8
- 108090001007 Interleukin-8 Proteins 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010020853 Hypertonic bladder Diseases 0.000 claims 6
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 6
- 208000020629 overactive bladder Diseases 0.000 claims 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 claims 1
- OUGCUPYREMACGK-ZETCQYMHSA-N (2s)-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 OUGCUPYREMACGK-ZETCQYMHSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- PJAAESPGJOSQGZ-DZGBDDFRSA-N Isovelleral Chemical compound O=CC1=C[C@@H]2CC(C)(C)C[C@@H]2[C@@]2(C)C[C@]21C=O PJAAESPGJOSQGZ-DZGBDDFRSA-N 0.000 claims 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 1
- 229940126422 TRPV1 antagonist Drugs 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229960001312 tiaprofenic acid Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (11)
1. Inhibitor IL-8 za primjenu u liječenju i/ili prevenciji intersticijalnog cistitisa/sindroma bolnog mjehura (IC/PBS) i/ili hiperaktivnog mjehura (OAB), koji je inhibitor CXCR1 ili dvostruki inhibitor CXCR1 i CXCR2 koji ima formulu (I)
[image]
ili farmaceutski prihvatljiva sol istog, pri čemu
R1 je vodik;
X je OH;
R2 je vodik ili linearni C1-C4 alkil;
Y je heteroatom odabran od S, O i N;
Z je odabran od linearnog ili račvastog C1-C4 alkila, linearnog ili račvastog C1-C4 alkoksi, halo C1-C3 alkila i halo C1-C3 alkoksi; ili
koji ima formulu (II)
[image]
ili farmaceutski prihvatljiva sol istog, pri čemu
R' je vodik;
R je ostatak formule SO2Ra pri čemu Ra je linearni ili račvasti C1-C4 alkil ili halo C1-C3 alkil.
2. Inhibitor IL-8 za primjenu prema patentnom zahtjevu 1, pri čemu su navedeni IC/PBS i/ili hiperaktivni mjehur (OAB) induciran terapijom protiv raka ili radioterapijom karlice.
3. Inhibitor IL-8 za primjenu prema patentnim zahtjevima 1 ili 2, pri čemu je navedeni inhibitor IL-8 odabran od (R,S)-2-(4-{[4-(trifluorometil)-1,3-tiazol-2-il]amino}fenil)propanske kiseline i (2S)-2-(4-{[4-(trifluorometil)-1,3-tiazol-2-il] amino} fenil) propanske kiseline, poželjno kao natrijeva sol.
4. Inhibitor IL-8 za primjenu prema patentnim zahtjevima 1 do 3, pri čemu je navedeni inhibitor IL-8 R(-)-2-[(4'-trifluorometansulfoniloksi)fenil]-N-metansulfonil propionamid, poželjno njegova natrijeva sol.
5. Farmaceutska kompozicija koja sadrži inhibitor IL-8 za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4.
6. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 5, koja dalje sadrži najmanje još jedan farmaceutski aktivan spoj.
7. Proizvod ili kit za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, koji sadrži:
A) Inhibitor IL-8 prema bilo kojem od patentnih zahtjeva 1 do 4, ili farmaceutsku kompoziciju prema patentnom zahtjevu 5, i
B) najmanje još jedan farmaceutski aktivan spoj
pri čemu su A) i B) dvije odvojene formulacije za istovremenu, odvojenu ili sekvencijalnu primjenu.
8. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 6 ili kit za primjenu prema patentnom zahtjevu 7, pri čemu je spomenuti dalje farmaceutski aktivan spoj aktivan spoj koristan za prevenciju i liječenje IC/PBS, i/ili OAB.
9. Farmaceutska kompozicija ili komplet za primjenu prema patentnom zahtjevu 8, pri čemu je spomenuti dalje farmaceutski aktivan spoj antagonist TRPV1.
10. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 6 ili kit za primjenu prema patentnom zahtjevu 7, pri čemu je spomenuti dalje farmaceutski aktivan spoj lijek koji inducira, kao neželjeni efekt, IC /PBS ili OAB.
11. Farmaceutska kompozicija ili komplet za primjenu prema patentnom zahtjevu 10 pri čemu je spomenuti dalje farmaceutski aktivan spoj odabran od ciklofosfamida, Bacillus Calmette-Guerin-a za instalaciju direktno u mjehur, mitomicina C, adriamicina ili tiaprofenske kiseline.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176726.6A EP3117835A1 (en) | 2015-07-14 | 2015-07-14 | Il-8 inhibitors for use in the treatment of certain urological disorders |
| EP16738165.6A EP3322438B1 (en) | 2015-07-14 | 2016-07-12 | Il-8 inhibitors for use in the treatment of certain urological disorders |
| PCT/EP2016/066511 WO2017009323A1 (en) | 2015-07-14 | 2016-07-12 | Il-8 inhibitors for use in the treatment of certain urological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211574T1 true HRP20211574T1 (hr) | 2022-02-04 |
Family
ID=53757997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211574TT HRP20211574T1 (hr) | 2015-07-14 | 2016-07-12 | Inhibitori il-8 za primjenu u liječenju određenih uroloških poremećaja |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20180200231A1 (hr) |
| EP (2) | EP3117835A1 (hr) |
| JP (1) | JP6937738B2 (hr) |
| KR (1) | KR102622924B1 (hr) |
| CN (1) | CN107921105B (hr) |
| AU (1) | AU2016292902B2 (hr) |
| BR (1) | BR112018000676A2 (hr) |
| CA (1) | CA2991810A1 (hr) |
| CY (1) | CY1125437T1 (hr) |
| DK (1) | DK3322438T3 (hr) |
| EA (2) | EA201890312A1 (hr) |
| ES (1) | ES2894077T3 (hr) |
| HR (1) | HRP20211574T1 (hr) |
| HU (1) | HUE056439T2 (hr) |
| IL (1) | IL256413B (hr) |
| LT (1) | LT3322438T (hr) |
| MA (1) | MA42437A (hr) |
| MD (1) | MD3322438T2 (hr) |
| MX (1) | MX2018000539A (hr) |
| NZ (1) | NZ739077A (hr) |
| PL (1) | PL3322438T3 (hr) |
| PT (1) | PT3322438T (hr) |
| RS (1) | RS62413B1 (hr) |
| SI (1) | SI3322438T1 (hr) |
| WO (1) | WO2017009323A1 (hr) |
| ZA (1) | ZA201708608B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
| CN114712377B (zh) * | 2022-04-26 | 2023-08-15 | 江苏师范大学 | 断血流皂苷a在制造药物中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996025157A1 (en) * | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| ES2333445T3 (es) * | 2004-03-23 | 2010-02-22 | Dompe' S.P.A. | Derivados del acido 2-fenilpropionico y composiciones farmaceuticas que los contienen. |
| EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| WO2010078403A2 (en) | 2008-12-30 | 2010-07-08 | Lipella Pharmaceuticals Inc. | Methods and compositions for diagnosing urological disorders |
| KR101458947B1 (ko) * | 2013-03-05 | 2014-11-12 | 국립암센터 | 인터루킨-８ 앱타머 및 이의 용도 |
-
2015
- 2015-07-14 EP EP15176726.6A patent/EP3117835A1/en not_active Withdrawn
-
2016
- 2016-07-12 NZ NZ739077A patent/NZ739077A/en unknown
- 2016-07-12 DK DK16738165.6T patent/DK3322438T3/da active
- 2016-07-12 MD MDE20180523T patent/MD3322438T2/ro not_active IP Right Cessation
- 2016-07-12 CA CA2991810A patent/CA2991810A1/en active Pending
- 2016-07-12 US US15/743,721 patent/US20180200231A1/en active Pending
- 2016-07-12 SI SI201631353T patent/SI3322438T1/sl unknown
- 2016-07-12 RS RS20211225A patent/RS62413B1/sr unknown
- 2016-07-12 PL PL16738165T patent/PL3322438T3/pl unknown
- 2016-07-12 MA MA042437A patent/MA42437A/fr unknown
- 2016-07-12 HR HRP20211574TT patent/HRP20211574T1/hr unknown
- 2016-07-12 HU HUE16738165A patent/HUE056439T2/hu unknown
- 2016-07-12 EA EA201890312A patent/EA201890312A1/ru unknown
- 2016-07-12 EP EP16738165.6A patent/EP3322438B1/en active Active
- 2016-07-12 JP JP2018501937A patent/JP6937738B2/ja active Active
- 2016-07-12 LT LTEPPCT/EP2016/066511T patent/LT3322438T/lt unknown
- 2016-07-12 ES ES16738165T patent/ES2894077T3/es active Active
- 2016-07-12 EA EA202190242A patent/EA202190242A1/ru unknown
- 2016-07-12 MX MX2018000539A patent/MX2018000539A/es unknown
- 2016-07-12 AU AU2016292902A patent/AU2016292902B2/en active Active
- 2016-07-12 WO PCT/EP2016/066511 patent/WO2017009323A1/en active Application Filing
- 2016-07-12 KR KR1020187003415A patent/KR102622924B1/ko active IP Right Grant
- 2016-07-12 PT PT16738165T patent/PT3322438T/pt unknown
- 2016-07-12 CN CN201680040741.XA patent/CN107921105B/zh active Active
- 2016-07-12 BR BR112018000676A patent/BR112018000676A2/pt active Search and Examination
-
2017
- 2017-12-18 ZA ZA2017/08608A patent/ZA201708608B/en unknown
- 2017-12-19 IL IL256413A patent/IL256413B/en active IP Right Grant
-
2021
- 2021-10-13 CY CY20211100885T patent/CY1125437T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3322438T3 (pl) | 2022-01-03 |
| SI3322438T1 (sl) | 2021-11-30 |
| MD3322438T2 (ro) | 2022-01-31 |
| NZ739077A (en) | 2023-12-22 |
| ZA201708608B (en) | 2019-05-29 |
| AU2016292902A1 (en) | 2018-01-18 |
| RS62413B1 (sr) | 2021-10-29 |
| IL256413B (en) | 2021-04-29 |
| MA42437A (fr) | 2021-06-02 |
| BR112018000676A2 (pt) | 2018-09-18 |
| PT3322438T (pt) | 2021-10-01 |
| US20180200231A1 (en) | 2018-07-19 |
| CN107921105B (zh) | 2022-08-02 |
| CN107921105A (zh) | 2018-04-17 |
| CA2991810A1 (en) | 2017-01-19 |
| LT3322438T (lt) | 2021-10-25 |
| IL256413A (en) | 2018-02-28 |
| JP2018520184A (ja) | 2018-07-26 |
| ES2894077T3 (es) | 2022-02-11 |
| MX2018000539A (es) | 2018-09-06 |
| EA202190242A1 (ru) | 2021-11-30 |
| HUE056439T2 (hu) | 2022-02-28 |
| JP6937738B2 (ja) | 2021-09-22 |
| KR102622924B1 (ko) | 2024-01-09 |
| DK3322438T3 (da) | 2021-10-18 |
| EA201890312A1 (ru) | 2018-08-31 |
| EP3322438A1 (en) | 2018-05-23 |
| KR20180030075A (ko) | 2018-03-21 |
| EP3322438B1 (en) | 2021-09-08 |
| AU2016292902B2 (en) | 2021-06-03 |
| EP3117835A1 (en) | 2017-01-18 |
| CY1125437T1 (el) | 2023-03-24 |
| WO2017009323A1 (en) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013021A2 (es) | Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| NZ708593A (en) | Novel pyrazole derivative | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| PE20151091A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
| MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| EA201391018A1 (ru) | Препараты иммуносупрессантов | |
| MX2019012827A (es) | Derivados de tetrahidronaftilo urea novedosos. |